ReviewHeliyon2024
A review on the in vitro and in vivo screening of α-glucosidase inhibitors.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Comparative evaluation of green-synthesized CeONanoscale advances · 2026Article
- Vincoside Lactam from EdibleFoods (Basel, Switzerland) · 2026Article
- Electron-buffering effect of CeAnalytical and bioanalytical chemistry · 2026Article
- Lichen-Derived Bioactive Compounds in Diabetes and Cardiovascular Risk: Experimental Evidence, Mechanisms, and Translational Challenges.Biomedicines · 2026Review
- Phytochemical Analysis, Antioxidant Activity, and Inhibition of Digestive Enzymes ofMolecules (Basel, Switzerland) · 2026Article
- Diphenylpiperazine attached to different triazole acetamide derivatives as a potent α-glucosidase inhibitor, new insight into the in silico study of an uncompetitive inhibitor.Journal of computer-aided molecular design · 2026Article
- Inhibition of Diabetes-Related Enzymes by Plant Secondary Metabolites: A Promising Therapeutic Strategy.Life (Basel, Switzerland) · 2026Review
- Understanding the Antihyperglycemic Activity ofMolecules (Basel, Switzerland) · 2026Article
- Article
- α-Glucosidase-driven metabolism as a potential therapeutic vulnerability inFrontiers in microbiology · 2026Review
- Physicochemical Analysis and Digestive Enzymes Inhibition of a Selected MalaysianFoods (Basel, Switzerland) · 2025Article
- Identification of novel triazolopyrimidines as potent α-glucosidase inhibitor through design, synthesis, biological evaluations, and computational analysis.Scientific reports · 2025Article
- Effects ofFoods (Basel, Switzerland) · 2025Article
- Antihyperglycemic drug screening: 4-nitrophenol intermittent pulse amperometry as a convenient α-glucosidase inhibitor assay.RSC advances · 2025Article
- Proximate Composition, Phytochemicals, Phenolic Compounds, and Bioactive Characterization ofPlants (Basel, Switzerland) · 2025Article
- Design and synthesis of novel quinoline-piperazines fused to a phenylhydrazinecarbothioamide scaffold as promising α-glucosidase inhibitors with anti-diabetic potential.Future medicinal chemistry · 2025Article
- Design, synthesis, and evaluation of triazolo[1,5-a]pyridines as novel and potent α‑glucosidase inhibitors.Scientific reports · 2025Article
- Chemical Composition, Antioxidant, and Enzyme Inhibitory Activities ofBiomolecules · 2025Article
- Design, synthesis, and investigation of novel 5-arylpyrazole-glucose hybrids as α-glucosidase inhibitors.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a global metabolic disease, the control and treatment of diabetes have always been the focus of medical research. α-Glucosidase is a key enzyme in regulating blood glucose levels and has important applications in the treatment of diabetes. This review aims to explore the enzyme activity of α-glucosidase and its inhibition mechanism and evaluate the efficacy and limitations of existing inhibitor screening methods. First, the chemical structure, biological activity, and influencing factors of α-glucosidase on diabetes are discussed in detail. Then, the various methods that have been used to screen α-glucosidase inhibitors in recent years are reviewed, including in vivo animal experiments, in vitro experiments, and virtual molecular docking. The experimental principles, advantages, and limitations of each method and their application in discovering new inhibitors are also discussed. Finally, this review emphasizes the importance of developing efficient and safe α-glucosidase inhibitors, summarizes the advantages and disadvantages of various screening models, and proposes future research directions. This review comprehensively examines the enzyme activity of α-glucosidase and the screening methods for α-glucosidase inhibitors, provides an important perspective in the field of diabetes drug discovery and development, and provides a reference for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.